Artificial Intelligence – Transforming Regulatory Affairs

Published 02nd October 2023

In the domain of Pharmaceutical Regulatory Affairs, regulatory agencies such as EMA and FDA are harnessing the potential of Artifical Intelligence (AI) to revolutionise assessment and oversight. While EMA and FDA are in consultation with stakeholders, we explore AI’s transformative impact and potential challenges ahead. AI enables machines to learn, think, and perform human like tasks, particularly excelling in data analysis and decision making.


Artificial Intelligence – Transforming Regulatory Affairs - Read more

Stay Informed

Sign up to our bimonthly newsletter for the latest news and industry insights

    Please check this box to submit the form and agree to communications from DLRC and the storage and handling of your data, in accordance with our Privacy Policy.

    Thank you for your submission.

    Latest news

    View all